PriceTargets.com logo

NASDAQ:NPCE - NeuroPace Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.80
  • Forecasted Upside: 74.37 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$15.37 As of 10/19/2021 04:37 PM ET
▼ -0.23 (-1.47%)

This chart shows the closing price for NPCE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NeuroPace Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NPCE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NPCE

Analyst Price Target is $26.80
▲ +74.37% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for NeuroPace in the last 3 months. The average price target is $26.80, with a high forecast of $30.00 and a low forecast of $25.00. The average price target represents a 74.37% upside from the last price of $15.37.

This chart shows the closing price for NPCE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in NeuroPace.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/21/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/17/2021Robert W. BairdInitiated CoverageOutperform$26.00Medium
8/15/2021SVB LeerinkReiterated RatingBuy$30.00Medium
6/3/2021SVB LeerinkBoost Price TargetOutperform$25.00 ➝ $30.00Low
5/17/2021SVB LeerinkInitiated CoverageOutperform$25.00Medium
5/17/2021Wells Fargo & CompanyInitiated CoverageOverweight$25.00Medium
5/17/2021JPMorgan Chase & Co.Initiated CoverageOverweight$27.00Medium
5/17/2021Morgan StanleyInitiated CoverageOverweight$26.00Medium
(Data available from 10/19/2016 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2021

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

NeuroPace logo
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Read More

Today's Range

Now: $15.37
Low: $15.30
High: $15.62

50 Day Range

MA: $18.94
Low: $15.60
High: $23.78

52 Week Range

Now: $15.37
Low: $15.05
High: $27.38

Volume

2,506 shs

Average Volume

95,979 shs

Market Capitalization

$373.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of NeuroPace?

The following Wall Street analysts have issued stock ratings on NeuroPace in the last year: JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, SVB Leerink LLC, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for NPCE.

What is the current price target for NeuroPace?

5 Wall Street analysts have set twelve-month price targets for NeuroPace in the last year. Their average twelve-month price target is $26.80, suggesting a possible upside of 71.8%. SVB Leerink LLC has the highest price target set, predicting NPCE will reach $30.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $25.00 for NeuroPace in the next year.
View the latest price targets for NPCE.

What is the current consensus analyst rating for NeuroPace?

NeuroPace currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NPCE will outperform the market and that investors should add to their positions of NeuroPace.
View the latest ratings for NPCE.

How do I contact NeuroPace's investor relations team?

The official website for NeuroPace is www.neuropace.com.